{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:36:53Z","timestamp":1787726213712,"version":"build-2784847793"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>High-risk proliferative diabetic retinopathy (HR-PDR) is the advanced stage of diabetic retinopathy progression with poor prior treatment efficacy and high rates of blindness. This meta-analysis aims to compare the efficacy and safety of pan retinal photocoagulation (PRP) combined with intravitreal anti-vascular endothelial growth factor (aVEGF) (PRP + aVEGF) versus PRP monotherapy in HR-PDR patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A thorough search was performed through PubMed, Web of Science, EMBASE, and the Cochran Library from inception to December 18, 2022. Outcome measures included change in central macular thickness, best-corrected visual acuity, fluorescein angiography, incidence of undergoing vitrectomy, and adverse events during the follow-up period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eight studies (6 randomized controlled trials and 2 retrospective studies) with 375 eyes were included in this meta-analysis. There were no obvious differences in the changes of best-corrected visual acuity and fluorescein angiography between the PRP + aVEGF and PRP monotherapy groups. However, PRP + aVEGF group had a significant reduction in the change of central macula thickness (standard mean deviations = \u22121.44, 95%CI = \u22122.55 to \u22120.32, <jats:italic toggle=\"yes\">P<\/jats:italic> = .01) and the rate of undergoing vitrectomy (odds ratio = 0.20, 95%CI = 0.05\u20130.83, <jats:italic toggle=\"yes\">P<\/jats:italic> = .01). Additionally, the risks of vitreous hemorrhage and other complications were not significantly different between the 2 groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion subsections:<\/jats:title>\n            <jats:p>Our meta-analysis indicated that PRP + aVEGF might have potential benefits in the treatment of HR-PDR patients. However, given several limitations of this study, more research is needed to confirm our findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034856","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:12:30Z","timestamp":1696007550000},"page":"e34856","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Peng","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"},{"name":"Department of Ophthalmology, Liuzhou People\u2019s Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Liuzhou People\u2019s Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Liuzhou People\u2019s Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyi","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renshen","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0443-8773","authenticated-orcid":false,"given":"Minli","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41433-022-01931-9","article-title":"Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? the VITDEX study.","volume":"37","author":"Iglicki","year":"2023","journal-title":"Eye (Lond)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/424258","article-title":"New developments in the pathophysiology and management of diabetic retinopathy.","volume":"2013","author":"Abu El-Asrar","year":"2013","journal-title":"J Diabetes Res"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41433-021-01722-8","article-title":"Next-generation anti-VEGF agents for diabetic macular oedema.","volume":"36","author":"Iglicki","year":"2022","journal-title":"Eye (Lond)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ophtha.2020.12.019","article-title":"Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality.","volume":"128","author":"Modjtahedi","year":"2021","journal-title":"Ophthalmology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"107840","DOI":"10.1016\/j.diabres.2019.107840","article-title":"IDF diabetes atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.","volume":"157","author":"Thomas","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy.","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/IAE.0000000000002196","article-title":"Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the international retina group real-life 24-month multicenter study. The IRGREL-DEX study.","volume":"39","author":"Iglicki","year":"2019","journal-title":"Retina"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000492132","article-title":"Effectiveness and safety of intravitreal dexamethasone implant (ozurdex) in patients with diabetic macular edema: a real-world experience.","volume":"241","author":"Mello Filho","year":"2019","journal-title":"Ophthalmologica"},{"issue":"5 Suppl","key":"R9-20250504","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004397-198702740-00004","article-title":"Indications for photocoagulation treatment of diabetic retinopathy: diabetic retinopathy study report no. 14. The Diabetic Retinopathy Study Research Group.","volume":"27","year":"1987","journal-title":"Int Ophthalmol Clin"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/07853890.2022.2064541","article-title":"VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.","volume":"54","author":"Arrigo","year":"2022","journal-title":"Ann Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/ICU.0000000000000760","article-title":"Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature.","volume":"32","author":"Berrocal","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"976","DOI":"10.4103\/1673-5374.355743","article-title":"Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy.","volume":"18","author":"Tang","year":"2023","journal-title":"Neural Regen Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0140-6736(17)31194-7","article-title":"Proliferative diabetic retinopathy: laser or eye injection?","volume":"389","author":"Ting","year":"2017","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"R16-20250504","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group.","volume":"88","year":"1981","journal-title":"Ophthalmology"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy.","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s12325-017-0548-1","article-title":"Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges.","volume":"34","author":"Dervenis","year":"2017","journal-title":"Adv Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1475-1313.2010.00766.x","article-title":"Transforming scales of measurement of visual acuity at the group level.","volume":"30","author":"Khoshnood","year":"2010","journal-title":"Ophthalmic Physiol Opt"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab Plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study).","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000442026","article-title":"Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial.","volume":"235","author":"Figueira","year":"2016","journal-title":"Ophthalmologica"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10633-012-9322-5","article-title":"Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.","volume":"124","author":"Messias","year":"2012","journal-title":"Doc Ophthalmol"},{"key":"R28-20250504","first-page":"1","article-title":"Comparison of efficacy of combination therapy of an intravitreal injection of bevacizumab and photocoagulation versus pan retinal photocoagulation alone in high risk proliferative diabetic retinopathy.","volume":"37","author":"","year":"2021","journal-title":"Pak J Med Sci"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","article-title":"Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).","volume":"86","author":"Tonello","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s10792-021-01773-6","article-title":"Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy.","volume":"41","author":"Tao","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R31-20250504","first-page":"1772","article-title":"Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.","volume":"9","author":"Zhou","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000499540","article-title":"The role of steroids in the management of diabetic macular edema.","volume":"62","author":"Zur","year":"2019","journal-title":"Ophthalmic Res"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/jop.2012.0202","article-title":"Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.","volume":"29","author":"Yang","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5935\/0004-2749.20220006","article-title":"Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab.","volume":"85","author":"Rentiya","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"807687","DOI":"10.3389\/fendo.2022.807687","article-title":"Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment against PRP alone for diabetic retinopathy: a systematic review with meta-analysis.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/IAE.0b013e31819a5fc2","article-title":"Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy.","volume":"29","author":"Cho","year":"2009","journal-title":"Retina"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","article-title":"Treatment of diabetic macular edema.","volume":"19","author":"Kim","year":"2019","journal-title":"Curr Diab Rep"},{"key":"R38-20250504","first-page":"CD008081","article-title":"Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.","volume":"1","author":"Virgili","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OPTH.S182420","article-title":"Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab.","volume":"13","author":"Shakarchi","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0161-6420(92)31779-8","article-title":"Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.","volume":"99","author":"Flynn","year":"1992","journal-title":"Ophthalmology"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10633-018-9655-9","article-title":"Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.","volume":"137","author":"Messias","year":"2018","journal-title":"Doc Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:43:24Z","timestamp":1746326604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":41,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034856","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}